Premarin cream discontinued, tablets to follow: What are the alternatives?
Health Canada says some estrogen patch shortages may persist into early 2027 as Premarin cream and tablets leave Canada. CPhA’s November resource outlines hormonal, vaginal and nonhormonal alternatives.
In this article & details
Health Canada’s November 19 shortage notice says interruptions affecting some estrogen patch strengths may continue into early 2027, alongside the withdrawal of Premarin cream and planned end of tablet sales. The department points to a Canadian Pharmacists Association resource outlining treatment alternatives.
CPhA’s November 2026 Menopausal Hormone Therapy Shortage resource covers systemic hormones, local vaginal treatments and nonhormonal medicines. It also addresses monitoring after a switch, endometrial protection and confirming coverage through public formularies or private insurance.
Pfizer’s Premarin withdrawal covers cream and all three tablet strengths
Pfizer confirmed to Reuters on Nov. 12 that it is ending Canadian sales of Premarin vaginal cream and all three strengths of its Premarin tablets. No more batches of the cream are planned. The company expects its remaining tablet stock to last until around the middle of 2027, although higher demand could bring that forward.
Pfizer told Reuters the decision followed an internal review and did not result from a new safety, effectiveness or quality concern. In the manufacturer’s filings with Health Product Shortages Canada, Pfizer gave business reasons for the discontinuations.
The cream has been discontinued; tablets are still in the supply chain
The manufacturer’s report for Premarin vaginal cream lists Nov. 3 as the actual discontinuation date. The cream had already been in shortage since June. Pfizer’s separate reports for the 0.3 mg, 0.625 mg and 1.25 mg oral tablets all list June 30, 2027, as the anticipated discontinuation date. That date is a forecast; the stock remaining at any one pharmacy may differ.
The affected products contain conjugated estrogens. The vaginal cream is a local treatment, while the oral products are systemic hormone therapy. Pfizer told Reuters that the decision did not extend to the hospital-use intravenous Premarin formulation.
Patch shortages and a separate intravenous Premarin interruption
Health Canada identifies supply constraints involving some strengths of Bayer’s Climara and Sandoz’s Estalis, Estradot and Estradiol Derm patches. It attributes the interruptions to global demand and manufacturing pressures. The notice does not describe every patch strength as unavailable.
The notice also reports an anticipated shortage of intravenous Premarin from December 2026 through May 2027 because of a manufacturing disruption. The IV product treats abnormal uterine bleeding associated with hormonal imbalance; it is not indicated for menopausal hormone therapy. This is separate from Pfizer’s cream and tablet discontinuations.
Selected estrogen products marketed in Canada
CPhA identifies the following selected estrogen products in its shortage resource. All contain 17-beta estradiol. Their formulation, strength and DIN are listed below to distinguish the products considered when assessing alternatives.
| Product | Strength | DIN |
|---|---|---|
| Patches | ||
| ClimaraBayer Incorporated | 25 mcg | 02247499 |
| 50 mcg | 02231509 | |
| 75 mcg | 02247500 | |
| Estradiol DermSandoz Canada Inc. | 50 mcg | 02246967 |
| 75 mcg | 02246968 | |
| 100 mcg | 02246969 | |
| EstradotSandoz Canada Inc. | 25 mcg | 02245676 |
| 37.5 mcg | 02243999 | |
| 50 mcg | 02244000 | |
| 75 mcg | 02244001 | |
| 100 mcg | 02244002 | |
| Gels | ||
| DivigelSearchlight Pharma Inc. | 0.1% | 02424835 |
| 02424843 | ||
| 02424924 | ||
| EstrogelOrganon Canada Incorporated | 0.06% | 02238704 |
| Oral tablets | ||
| Lupin-EstradiolLupin Pharma Canada Limited | 0.5 mg | 02449048 |
| 1 mg | 02449056 | |
| 2 mg | 02449064 | |
Source: Canadian Pharmacists Association, Menopausal Hormone Therapy Shortage, November 2026, Table 1, page 1. Strengths, doses and adverse effects are those listed by CPhA.
Marketed status does not confirm local stock, insurance coverage or suitability for a particular patient. The products are not a list of universally interchangeable replacements for Premarin.
Combined and vaginal products are listed separately
CPhA’s second table covers combined estrogen/progestin products: Activelle LD, Activelle, Angeliq, Bijuva and Estalis.
For vaginal treatment, CPhA lists Estragyn vaginal cream, Estring, Imvexxy and Vagifem 10. Those options are presented separately from systemic therapies. The resource says vaginal estrogen can be used on its own for genitourinary syndrome of menopause or added when vaginal symptoms persist despite systemic treatment.
The product tables identify strengths, drug identification numbers and manufacturers. They are lists of selected marketed products, rather than a guarantee that each product is in stock at a particular pharmacy. CPhA directs readers to Health Product Shortages Canada for changing supply and discontinuation information.
Switching requires reassessment, monitoring and appropriate uterine protection
CPhA describes its document as support for clinicians managing shortages among patients already receiving treatment. It is not a comprehensive clinical practice guideline. The association says professional assessment and judgment remain necessary when selecting an alternative.
The resource identifies cost, adherence and patient preference as factors in choosing another hormonal treatment. It refers to the Canadian Menopause Society’s systemic hormone-therapy equivalency table as a general guide and calls for monitoring effectiveness and safety after a switch, with dose adjustments where needed.
It specifically addresses patients with an intact uterus moving from a combined systemic estrogen/progestogen product to systemic estrogen alone: a progestogen should be added to reduce the risk of endometrial hyperplasia. The document also discusses potential advantages of transdermal estrogen, including a potentially lower venous-thromboembolism risk than oral treatment in selected patients.
CPhA describes MHT as the most effective treatment for vasomotor symptoms in patients younger than 60 and less than 10 years past menopause who have no MHT contraindications. Its discussion does not present every formulation as suitable for every patient.
Table 5: Nonhormonal options for menopausal symptoms
CPhA discusses nonhormonal medicines for vasomotor symptoms when MHT is undesirable or contraindicated. Its listed doses and adverse effects are set out below to support professional assessment during a shortage.
| Medicine | Dose | Adverse effects |
|---|---|---|
| Alpha-2 adrenergic agonist | ||
| Clonidine | 0.05 mgOral Twice daily | Dizziness, dry mouth, drowsiness and constipation. |
| Anticholinergic agents | ||
| Oxybutynin | 2.5–5 mgOral Twice daily | Dry mouth, constipation and tachycardia. |
| Oxybutynin, extended release | 15 mgOral Daily | Dry mouth, constipation and tachycardia. |
| Gamma-aminobutyric acid derivatives | ||
| Gabapentin | 300 mgOral Three times daily | Somnolence and dizziness. |
| Pregabalin | 150–300 mgOral Daily total | Somnolence and dizziness. |
| Neurokinin receptor antagonists | ||
| Elinzanetant | 120 mgOral At bedtime | Headache, abdominal pain, diarrhea, nausea, dizziness, fatigue and seizure risk. |
| Fezolinetant | 45 mgOral Daily | Abdominal pain, diarrhea, insomnia, back pain and elevated liver-function tests. |
| Selective serotonin reuptake inhibitors | ||
| Citalopram | 10–20 mgOral Daily | Gastrointestinal upset, sexual dysfunction and weight gain. |
| Escitalopram | 10–20 mgOral Daily | Gastrointestinal upset, sexual dysfunction and weight gain. |
| Paroxetine | 10–20 mgOral Daily | Gastrointestinal upset, sexual dysfunction and weight gain. |
| Serotonin–norepinephrine reuptake inhibitors | ||
| Desvenlafaxine | 50–100 mgOral Daily | Gastrointestinal upset, dry mouth, drowsiness, nervousness and sexual dysfunction. |
| Venlafaxine | 37.5–75 mgOral Daily | Gastrointestinal upset, dry mouth, drowsiness, nervousness and sexual dysfunction. |
Source: Canadian Pharmacists Association, Menopausal Hormone Therapy Shortage, November 2026, Table 5, page 4. Strengths, doses and adverse effects are those listed by CPhA.
Table 6: Nonestrogen options for genitourinary symptoms
The resource lists the following nonestrogen therapies for genitourinary syndrome of menopause, including vaginal dryness and dyspareunia.
| Treatment | Dose / use | Adverse effects |
|---|---|---|
| Ospemifene oral tablet | 60 mg1 tablet, oral Daily | Hot flashes, vaginal discharge, muscle spasms and excessive sweating. |
| Prasterone vaginal ovule | 6.5 mg1 ovule, vaginal Daily | Vaginal discharge. |
| Vaginal lubricants | As needed | None listed in the CPhA table. |
| Vaginal moisturizers | Regular useFor example 2–3 times weekly | None listed in the CPhA table. |
Source: Canadian Pharmacists Association, Menopausal Hormone Therapy Shortage, November 2026, Table 6, page 5. Strengths, doses and adverse effects are those listed by CPhA.
CPhA lists conjugated estrogen/bazedoxifene and tibolone in a separate table of alternative hormonal products.
The document also notes uses of estrogen outside menopause care, including off-label feminizing hormone therapy for transgender and gender-diverse patients and add-back treatment during GnRH-agonist therapy. These uses are distinguished from the approved indications described in the resource.
CPhA asks health-care providers to help patients confirm that an alternative is covered under the applicable provincial formulary or private plan. Selection of another marketed product does not establish equivalent insurance coverage.
Health Canada continues supply monitoring
Health Canada says the resource’s alternatives are currently available without reported shortages. It is working with manufacturers, governments and other stakeholders and advises patients to discuss options with a doctor or pharmacist. The department also cautions against unlicensed sellers and unauthorized products.
Pfizer’s manufacturer reports remain the source for changes to the expected end of tablet supply. CPhA’s resource provides treatment options; it does not reverse the Premarin discontinuations.
References
- Pfizer confirmation of Canadian Premarin discontinuations — Reuters, Original company confirmation, Nov. 12, 2026
- Premarin vaginal cream discontinuation report — Pfizer Canada / Health Product Shortages Canada, Actual discontinuation Nov. 3, 2026
- Premarin 0.3 mg tablet discontinuation report — Pfizer Canada / Health Product Shortages Canada, Anticipated discontinuation June 30, 2027
- Premarin 0.625 mg tablet discontinuation report — Pfizer Canada / Health Product Shortages Canada, Anticipated discontinuation June 30, 2027
- Premarin 1.25 mg tablet discontinuation report — Pfizer Canada / Health Product Shortages Canada, Anticipated discontinuation June 30, 2027
- Menopause Hormone Therapy – Estradiol Transdermal Patches and Conjugated Estrogen Drugs in short supply in Canada: Notice — Health Canada, Notice dated November 19, 2026
- Menopausal Hormone Therapy Shortage — Canadian Pharmacists Association, November 2026 edition; accessed November 19, 2026
Discussion
0 commentsJoin the discussion. Anyone can read the comments. To comment, log in or create a free individual account.
No comments yet.